Cloning, expression and polyclonal antibody preparation of the asialoglycoprotein receptor of Marmota Himalayan

Abstract

The objective of this study is to express the carbohydrate recognition domain (CRD) of the asialoglycoprotein receptor (ASGPR) H1 and H2 subunits of Marmota himalayan in vitro, and develop polyclonal antibodies against the recombinant proteins. RT-PCR was used to amplify ASGPR CRDH1 and CRDH2 from the liver tissue of Marmota himalayan. The products of amplification were subcloned into prokaryotic expression vector pRSET-B, and expressed in E.coli BL21(DE3)plysS. The recombinant proteins were purified using Ni-NTA spin column. The purified proteins were inoculated into BALB/c mice to develop polyclonal antibodies. The sensitivity and specificity of antibodies were evaluated by enzyme-linked immunosorbent assay (ELISA), Western blotting and immunohistochemical staining (IHC). The polyclonal antibodies showed high sensitivity and specificity against both denaturated and native ASGPR proteins. We successfully amplified and expressed the ASGPR CRDs of Marmota himalayan. The nucleic sequences of ASGPR CRDH1 and CRDH2 of Marmota himalayan have been submitted to Genbank and the sequence ID are DQ 845465 and DQ845466, respectively. The proteins and antibodies prepared can be used for targeting gene therapy in a new animal model—Marmota Himalayan—for the research of infectious diseases of hepatitis viruses and liver cancer treatment.

Keywords

asialoglycoprotein receptor / Marmota himalayan / polyclonal antibody / targeted therapy

References

[1] Hervas-StubbsS., LasarteJ. J., SarobeP., et al.. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol, 1997, 27: 726-737

[2] LuM., RoggendorfM.. Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model. Inter Virol, 2001, 44: 124-131

[3] LiuS. P., JiangS. Y., YiH., et al.. Identity of hepatitis virus in Qinghai Marmota Himalayan similarwith human hepatitis B virus. Qinghai Med J (Chinese), 1987, 5: 123

[4] JinZ. H., ZhaoG. L., ZiongS. S., et al.. An experimental transmission of woodchuck hepatitis virus to young Chinese marmots. Hepatology, 1988, 8(2): 371-373

[5] ZhangJ., WangB. J., MengZ. J., et al.. Immunohistochemical study of hepadnavirus surface antigenexpression in liver tissue of marmota baibacina. Hua Zhong Yi Xue Za Zhi (Chinese), 2003, 27: 231-232

[6] StockertR. J.. The asialoglycoprotein receptors: relationships between structure, function, and expression. Physiol Rev, 1995, 75(3): 591-593

[7] MeierM., BiderM. D., MalashkevichV. N., et al.. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Bio, 2000, 300: 857-865

[8] WuG. Y., WuC. H.. Delivery systems for gene therapy. Biotherapy, 1991, 3(1): 87-95

[9] ShenkmanM., EhrlichM., LederkremerG. Z.. Masking of an endoplasmic reticulum retention signal by its presence in the two subunits of the asialoglycoprotein receptor. J Bio Chem, 2000, 275(4): 2845-2851

[10] SaunierB., TriyatniM., UlianichL., et al.. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol, 2003, 77(1): 546-559

[11] HuangH., YangY., LiuJ., et al.. Prokaryotic expression, purification and renaturation of CRDH1 and CRDH2 of Chinese marmata Asialoglycoprote in receptor. J Med Mol Biol (Chinese), 2006, 3(4): 255-259

[12] GuoP. X., EricksonS., AndersonD.. A small viral RNA is required for in vitro packaging of bacteriophage phi29 DNA. Science, 1987, 236(4802): 690-694

[13] ZhangZ. M., TianY. J., YangY., et al.. Inhibition of hepatitis B virus replication by pRNA-escorted siRNA. Virologica Sinaca (Chinese), 2006, 21(6): 599-603

[14] TuerkC., GoldL.. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249: 505-510

[15] EllingtonA. D., SzostakJ.. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346: 818-822

[16] GuoS. C., TschammerN., MohammedS., et al.. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gen Ther, 2005, 16: 1097-1109